Navigation Links
Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics
Date:10/29/2008

Spectranetics Replaces President and CEO John G. Schulte with Chairman

Emile J. Geisenheimer.

SEATTLE, Oct. 29 /PRNewswire/ -- Hagens Berman Sobol Shapiro filed a class-action lawsuit on behalf of those who purchased Spectranetics Company stock (Nasdaq: SPNC), claiming the company, its chief executive officer and chief financial officer violated U.S. securities laws through illegal marketing practices and false statements about the company's financial health. If you are interested in serving as lead plaintiff, the deadline for filing is Nov. 24, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO)

Last week, Spectranetics announced the appointment of chairman Emile J. Geisenheimer to president and CEO, ousting John G. Schulte, a named defendant in the class action suit. Geisenheimer issued a statement that he has an "understanding of the challenges before us, and the board of directors and I are confident that we are taking an important step towards putting these challenges behind us so that we can build a stronger future for our company."

The class action was filed after a former employee filed suit against the company claiming Spectranetics fired him after he informed senior management of potentially illegal marketing practices with some of the company's products.

According to court documents, shortly thereafter, the Denver office of the Securities and Exchange Commission (SEC) began its own investigation into the company sparking further speculation about the company and its practices.

"Investors across the country are on shaky ground these days," said Reed Kathrein, lead attorney and partner at Hagens Berman Sobol Shapiro. "Spectranetics, like many companies, fell prey to a bad market and unfortunately decided to mislead investors to try and turn things around."

The lawsuit seeks to represent anyone who purchased or acquired company stock between April 19, 2007 and Sept. 4, 2008.

The lawsuit alleges company executives issued false and misleading statements concerning operations and finances, which caused company stock to trade at an artificially inflated price. Defendants knowingly shared misinformation and failed to communicate accurate reports, the complaint states.

The shock came to investors on Sept. 4, 2008 when reports surfaced that federal officials raided the company. Almost immediately, NASDAQ halted trading of Spectranetics stock.

According to court documents, Spectranetics issued a press release revealing more information about the search warrants, disclosing the company was jointly served by the FDA and U.S. Immigration and Customs Enforcement regarding the promotion, use, testing, marketing and sales of certain Spectranetics products. The warrants also addressed payments made to medical personnel.

The suit claims the effect on company stock was significant as it fell 47 percent to $4.73 per share. Today the company stock stands at $2.74, after trading at a high of $16.00 per share in December 2007.

The allegations against Spectranetics include: failing to notify investors and the public that the company lacked effective regulatory compliance controls; illegally and extensively marketing its laser and catheters for uses not approved by the FDA; failing to report to the FDA that tests found its laser caused significant damage to stents when used in clinical trials; illegally testing several products without FDA approval; the company's lack of effective internal controls and the material inflation of the company's financial results.

The complaint alleges the defendants, which include The Spectranetics Corporation, John G. Schulte, president and CEO, and Guy A. Childs, vice president and CFO, violated several sections of the 1934 Securities Exchange Act.

If you invested in Spectranetics stock during the outlined class period, you may be eligible to join this suit and move to be a lead plaintiff. The deadline for moving is Nov. 24, 2008. You can contact plaintiff's counsel, Reed Kathrein at (510) 725-3000, or via e-mail at info@hbsslaw.com.

More information on this lawsuit is available at http://www.hbsslaw.com/spnc.

About Hagens Berman Sobol Shapiro

Hagens Berman Sobol Shapiro is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix, San Francisco and New York. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation, one of the largest anti-trust settlements in history; a $340 million recovery on behalf of Enron employees; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in an $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit http://www.hbsslaw.com.

CONTACTS:

Reed Kathrein (510) 725-3000 Mark Firmani (206) 443-9357

Hagens Berman Sobol Shapiro Firmani + Associates Inc.

Reed@hbsslaw.com Mark@firmani.com


'/>"/>
SOURCE Hagens Berman Sobol Shapiro
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation
2. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
3. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
4. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
5. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
6. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
7. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
8. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
9. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
10. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
11. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: